Lipid II as a target for antibiotics

Nature Reviews Drug Discovery

Volumn 5, Issue 4, 2006, Pages 321-323

  Breukink, Eefjan ^a   de Kruijff, Ben ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AC 986446; ANTIBIOTIC AGENT; DALBAVANCIN; KATANOSIN B; LANTIBIOTIC; MANNOPEPTIMYCIN; MERSACIDIN; MUTACIN B NY266; NISIN; ORITAVANCIN; PLUSBACIN A3; POLYPEPTIDE ANTIBIOTIC AGENT; RAMOPLANIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACILLUS; BACTERIAL CELL WALL; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENTEROCOCCUS; HUMAN; LACTOBACILLUS; MICROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIOCINS; CELL WALL; DEPSIPEPTIDES; DRUG RESISTANCE, BACTERIAL; GLYCOPEPTIDES; MOLECULAR SEQUENCE DATA; NISIN; PEPTIDES; URIDINE DIPHOSPHATE N-ACETYLMURAMIC ACID;

EID: 33645474378     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2004     Document Type: Review

References (98)

1. Weigel, L. M. et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302, 1569-1571 (2003).
2. Harz, H., Burgdorf, K. & Holtje, J.-V. Isolation and separation of the glycan strands from murein of Escherichia coli by reversed-phase high-performance liquid chromatography. Anal. Biochem. 190, 120-128 (1990).
3. Kramer, N. E. et al. Resistance of Gram-positive bacteria to nisin is not determined by Lipid II levels. FEMS Microbiol. Lett. 239, 157-161 (2004).
4. Stone, K. J. & Strominger, J. L. Binding of bacitracin to cells and protoplasts of Micrococcus lysodeikticus. J. Biol. Chem. 249, 1823-1827 (1973).
5. Labischinski, H., Goodell, E. W., Goodell, A. & Hochberg, M. L. Direct proof of a more than single-layered' peptidoglycan architecture of Escherichia coli. J. Bacteriol. 136, 723-729 (1991).
6. McCloskey, M. A. & Troy, F. A. Paramagnetic isoprenoid carrier lipids. 2. Dispersion and dynamics in lipid membranes. Biochemistry 19, 2061-2066 (1980).
7. Chatterjee, C., Paul, M., Xie, L. L. & van der Donk, W. A. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 105, 633-683 (2005).
8. Ekkelenkamp, M. B. et al. Isolation and structural characterization of epilancin 15X, a novel lantibiotic from a clinical strain of Staphylococcus epidermidis. FEBS Lett. 579, 1917-1922 (2005).
9. Rogers, L. A. The inhibiting effect of Streptococcus lactis on Lactobacillus bulgaricus. J. Bacteriol. 16, 321-325 (1928).
10. Rogers, L. A. & Whittier, E. O. Limiting factors in the lactic fermentation. J. Bacteriol. 16, 211-229 (1928).
11. Delves-Broughton, J., Blackburn, P., Evans, R. J. & Hugenholtz, J. Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek 69, 193-202 (1996).
12. Linnett, P. E. & Strominger, J. L. Additional antibiotic inhibitors of peptidoglycan synthesis. J. Biol. Chem. 4, 231-236 (1973).
13. Reisinger, P., Seidel, H., Tschesche, H. & Hammes, W. P. The effect of nisin on murein synthesis. Arch. Microbiol. 127, 187-193 (1980).
14. Sahl, H.-G. in Nisin and Novel Lantibiotics (eds. Jung, G. & Sahl, H.-G.) 347-358 (ESCOM Science, Leiden, 1991).
15. Ruhr, E. & Sahl, H. G. Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob. Agents Chemother. 27, 841-845 (1985).
16. Garcera, M. J., Elferink, M. G., Driessen, A. J. & Konings, W. N. In vitro pore-forming activity of the lantibiotic nisin. Role of protonmotive force and lipid composition. Eur. J. Biochem. 212, 417-422 (1993).
17. Breukink, E. et al. The C-terminal region of nisin is responsible for the initial interaction of nisin with the target membrane. Biochemistry 36, 6968-6976 (1997).
18. Breukink, E., Ganz, P., de Kruijff, B. & Seelig, J. Binding of nisin Z to bilayer vesicles as determined with isothermal titration calorimetry. Biochemistry 39, 10247-10254 (2000).
19. Martin, I., Ruysschaert, J. M., Sanders, D. & Giffard, C. J. Interaction of the lantibiotic nisin with membranes revealed by fluorescence quenching of an introduced tryptophan. Eur. J. Biochem. 239, 156-164 (1996).
20. Brotz, H. et al. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30, 317-327 (1998).
21. Breukink, E. et al. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286, 2361-2364 (1999).
22. Matsuzaki, K., Murase, O., Fujii, N. & Miyajima, K. Translocation of a channel-forming antimicrobial peptide, magainin 2, across lipid bilayers by forming a pore. Biochemistry 34, 6521-6526 (1995).
23. van Kraaij, C. et al. Pore formation by nisin involves translocation of its C-terminal part across the membrane. Biochemistry 37, 16033-16040 (1998).
24. Brogden, K. A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nature Rev. Microbiol. 3, 238-250 (2005).
25. Wiedemann, I. et al. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276, 1772-1779 (2001).
26. Breukink, E. et al. The orientation of nisin in membranes. Biochemistry 37, 8153-8162 (1998).
27. Sahl, H. G., Kordel, M. & Benz, R. Voltage-dependent depolarization of bacterial membranes and artificial lipid bilayers by the peptide antibiotic nisin. Arch. Microbiol. 149, 120-124 (1987).
28. van Heusden, H. E., de Kruijff, B. & Breukink, E. Lipid II induces a transmembrane orientation of the pore forming peptide lantibiotic nisin. Biochemistry 41, 12171-12178 (2002).
29. Wiedemann, I., Benz, R. & Sahl, H.-G. Lipid II-mediated pore formation by the peptide antibiotic nisin - a black lipid membrane study. J. Bacteriol. 186, 3259-3261 (2004).
30. Breukink, E. et al. Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J. Biol. Chem. 278, 19898-19903 (2003).
31. Bonev, B. B., Breukink, E., Swiezewska, E., de Kruijff, B. & Watts, A. Targeting extracellular pyrophosphates underpins the high selectivity of nisin. FASEB J. 18, 1862-1869 (2004).
32. Hasper, H. E., de Kruijff, B. & Breukink, E. Assembly and stability of nisin-Lipid II pores. Biochemistry 43, 11567-11575 (2004).
33. Hsu, S. T. D. et al. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nature Struct. Mol. Biol. 11, 963-967 (2004).
34. Chan, W. C. et al. Structure-activity relationships in the peptide antibiotic nisin: Antibacterial activity of fragments of nisin. FEBS Lett. 390, 129-132 (1996).
35. Arthur, M. & Courvalin, P. Genetics and mechanisms of glycopeptide resistance in Enterococci. Antimicrob. Agents Chemother. 37, 1563-1571 (1993).
36. Brotz, H., Bierbaum, G., Leopold, K., Reynolds, P. E. & Sahl, H.-G. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting Lipid II. Antimicrob. Agents Chemother. 42, 154-160 (1998).
37. Hsu, S. T. D. et al. NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles - conformational changes are a key to antimicrobial activity. J. Biol. Chem. 278, 13110-13117 (2003).
38. Martin, N. I. et al. Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry 43, 3049-3056 (2004).
39. Cavalleri, B., Pagani, H., Volpe, G., Selva, E. & Parenti, F. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J. Antibiot. (Tokyo) 37, 309-317 (1984).
40. McCafferty, D. G. et al. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 66, 261-284 (2002).
41. Walker, S. et al. Chemistry and biology of ramoplanin: A lipoglycodepsipeptide with potent antibiotic activity. Chem. Rev. 105, 449-476 (2005).
42. Cudic, P. et al. Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: Minimal structural requirements for intermolecular complexation and fibril formation. Proc. Natl Acad. Sci. USA 99, 7384-7389 (2002).
43. Rew, Y., Shin, D., Hwang, I. & Boger, D. L. Total synthesis and examination of three key analogues of ramoplanin: A lipoglycodepsipeptide with potent antibiotic activity. J. Am. Chem. Soc. 126, 1041-1043 (2004).
44. Jiang, W., Wanner, J., Lee, R. J., Bounaud, P. Y. & Boger, D. L. Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J. Am. Chem. Soc. 125, 1877-1887 (2003).
45. Helm, J. S., Chen, L. & Walker, S. Rethinking ramoplanin: The role of substrate binding in inhibition of peptidoglycan biosynthesis. J. Am. Chem. Soc. 124, 13970-13971 (2002).
46. Ciabatti, R., Maffioli, S. I., Romano, G., Candiani, G. & Panzone, G. A process for the production of ramoplanin-like amide derivatives. Chem. Abstr. 139, 261566 (2003).
47. Chen, L. et al. Dissecting ramoplanin: Mechanistic analysis of synthetic ramoplanin analogues as a guide to the design of improved antibiotics. J. Am. Chem. Soc. 126, 7462-7463 (2004).
48. Cudic, P. et al. Functional analysis of the lipoglycodepsipeptide antibiotic ramoplanin. Chem. Biol. 9, 897-906 (2002).
49. Watson, J. D. & Milner-White, E. J. A novel main-chain anion-binding site in proteins: The nest. A particular combination of phi, psi values in successive residues gives rise to anion-binding sites that occur commonly and are found often at functionally important regions. J. Mol. Biol. 315, 171-182 (2002).
50. Watson, J. D. & Milner-White, E. J. The conformations of polypeptide chains where the main-chain parts of successive residues are enantiomeric. Their occurrence in cation and anion-binding regions of proteins. J. Mol. Biol. 315, 183-1191 (2002).
51. Singh, M. P. et al. Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities. Antimicrob. Agents Chemother. 47, 62-69 (2003).
52. He, H. et al. Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J. Am. Chem. Soc. 124, 9729-9736 (2002).
53. Dushin, R. G. et al. Hydrophobic acetal and ketal derivatives of mannopeptimycin-α and desmethylhexahydromannopeptimycin-α: semisynthetic glycopeptides with potent activity against Gram-positive bacteria. J. Med. Chem. 47, 3487-3490 (2004).
54. Ruzin, A. et al. Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 48, 728-738 (2004).
55. Shoji, J. et al. Isolation and characterization of new peptide antibiotics, plusbacins A1-A4 and B1-B4. J. Antibiot. (Tokyo) 45, 817-823 (1992).
56. Shoji, J. et al. Isolation and characterization of katanosins A and B. J. Antibiot. (Tokyo) 41, 713-718 (1988).
57. 3, inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 1823-1827 (2001).
58. Jarvis, B. Resistance to nisin and production of nisin-inactivating enzymes by several Bacillus species. J. Gen. Microbiol. 47, 33-48 (1967).
59. Jarvis, B. & Farr, J. Partial purification, specificity and mechanism of action of the nisin-inactivating enzyme from Bacillus cereus. Biochim. Biophys. Acta 227, 232-240 (1971).
60. Froseth, B. R. & McKay, L. L. Molecular characterization of the nisin resistance region of Lactococcus-lactis subsp lactis biovar diacetylactis Drc3. Appl. Environ. Microbiol. 57, 804-811 (1991).
61. Mantovani, H. C. & Russell, J. B. Nisin resistance of Streptococcus bovis. Appl. Environ. Microbiol. 67, 808-813 (2001).
62. Breuer, B. & Radler, F. Inducible resistance against nisin in Lactobacillus casei. Arch. Microbiol. 165, 114-118 (1996).
63. Severina, E., Severin, A. & Tomasz, A. Antibacterial efficacy of nisin against multidrug-resistant Gram positive pathogens. J. Antimicrob. Chemother. 41, 341-347 (1998).
64. MaisnierPatin, S. & Richard, J. Cell wall changes in nisin-resistant variants of Listeria innocua grown in the presence of high nisin concentrations. FEMS Microbiol. Lett. 140, 29-35 (1996).
65. Verheul, A., Russell, N. J., van't Hof, R., Rombouts, F. M. & Abee, T. Modifications of membrane phospholipid composition in nisin-resistant Listeria monocytogenes Scott A. Appl. Environ. Microbiol. 63, 3451-3457 (1997).
66. Crandall, A. D. & Montville, T. J. Nisin resistance in Listeria monocytogenes ATCC 700302 is a complex phenotype. Appl. Environ. Microbiol. 64, 231-237 (1998).
67. Davies, E. A., Falahee, M. B. & Adams, M. R. Involvement of the cell envelope of Listeria monocytogenes in the acquisition of nisin resistance. J. Appl. Bacteriol. 81, 139-146 (1996).
68. Neuhaus, F. C. & Baddiley, J. A continuum of anionic charge: Structures and functions of D-Alanyl-Teichoic acids in Gram-positive bacteria. Microb. Mol. Biol. Rev. 67, 686-723 (2003).
69. Kramer, N. E. Nisin resistance in Gram-positive bacteria. Ph.D. Thesis, Utrecht Univ. (2005).
70. Cao, M. & Helmann, J. D. The Bacillus subtilis extracytoplasmic-function sigma(X) factor regulates modification of the cell envelope and resistance to cationic antimicrobial peptides. J. Bacteriol. 186, 1136-1146 (2004).
71. Farver, D. K., Hedge, D. D. & Lee, S. C. Ramoplanin: A lioglycodepsipeptide antibiotic. Ann. Pharmacother. 39, 863-868 (2005).
72. Brumfitt, W., Salton, M. R. J. & Hamilton-Miller, J. M. T. Nisin, alone and combined with peptidoglycanmodulating antibiotics: Activity against methicillinresistant Staphylococcus aureus and vancomycinresistant enterococci. J. Antimicrob. Chemother. 50, 731-734 (2002).
73. Bavin, E. M., Beach, A. S., Falconer, R. & Friedman, R. Nisin in experimental tuberculosis. The Lancet 259, 127-129 (1952).
74. Mota-Meira, M., LaPointe, G., Lacroix, C. & Lavoie, M. C. MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens. Antimicrob. Agents Chemother. 44, 24-29 (2000).
75. Peschel, A. et al. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274, 8405-8410 (1999).
76. Stevens, K. A., Sheldon, B. W., Klapes, N. A. & Klaenhammer, T. R. Nisin treatment for inactivation of Salmonella species and other Gram-negative bacteria. Appl. Environ. Microbiol. 57, 3613-3615 (1991).
77. Yuan, J., Zhang, Z. Z., Chen, X. Z., Yang, W. & Huan, L. D. Site-directed mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants. Appl. Microbiol. Biotechnol. 64, 806-815 (2004).
78. He, H. Mannopeptimycins, a novel class of glycopeptide antibiotics active against Gram-positive bacteria. Appl. Microbiol. Biotechnol. 67, 444-452 (2005).
79. Goldstein, B. P., Wei, J., Greenberg, K. & Novick, R. Activity of nisin against Streptococcus pneumoniae, in vitro, a mouse infection model. J. Antimicrob. Chemother. 42, 277-278 (1998).
80. Kordel, M. & Sahl, H. G. Susceptibility of bacterial, eukaryotic and artificial membranes to the disruptive action of the cationic peptides Pep 5 and nisin. FEMS Microbiol. Lett. 34, 139-144 (1986).
81. Chatterjee, S. et al. Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J. Antibiot. (Tokyo) 45, 839-845 (1992).
82. Kruszewska, D. et al. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 54, 648-653 (2004).
83. Weiss, W. J., Murphy, T., Lenoy, E. & Young, M. In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models. Antimicrob. Agents Chemother. 48, 1708-1712 (2004).
84. McCormick, M. H., McGuire, J. M., Pittenger, G. E., Pittenger, R. C. & Stark, W. M. Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot. Annu. 3, 606-611 (1956).
85. Williamson, M. P. & Williams, D. H. Structure revision of the antibiotic vancomycin. Use of nuclear Overhauser effect difference spectroscopy. J. Am. Chem. Soc. 103, 6580- 6585 (1981).
86. Sheldrick, G. M., Jones, P. G., Kennard, O., Williams, D. H. & Smith, G. A. Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine. Nature 271, 223-225 (1978).
87. Harris, C. M. & Harris, T. M. Structure of the glycopeptide antibiotic vancomycin. Evidence for an asparagine residue in the peptide. J. Am. Chem. Soc. 104, 4293-4295 (1982).
88. Anderson, J. S., Matsuhashi, M., Haskin, M. A. & Strominger, J. L. Lipid-phosphoacetylmuramylpentapeptide and lipid-phosphodisaccharide-pentapeptide: Presumed membrane transport intermediates in cell wall synthesis. Proc. Natl Acad. Sci. USA 53, 881-889 (1965).
89. Perkins, H. R. Specificity of combination between mucopeptide precursors and vancomycin or ristocetin. Biochem. J. 111, 195-205 (1969).
90. Chatterjee, A. N. & Perkins, H. R. Compounds formed between nucleotides related to the biosynthesis of bacterial cell wall and vancomycin. Biochem. Biophys. Res. Commun. 24, 489-494 (1966).
91. Bordet, C. & Perkins, H. R. Iodinated vancomycin and mucopeptide biosynthesis by cell-free preparations from Micrococcus lysodeikticus. Biochem. J. 119, 877-883 (1970).
92. Molinari, H., Pastore, A., Lian, L. Y., Hawkes, G. E. & Sales, K. Structure of vancomycin and a vancomycin/D-Ala-D-Ala complex in solution. Biochemistry 29, 2271-2277 (1990).
93. Vollmerhaus, P. J., Breukink, E. & Heck, A. J. Getting closer to the real bacterial cell wall target: Biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics. Chemistry 9, 1556-1565 (2003).
94. Malabarba, A. & Goldstein, B. P. Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. 55 (Suppl. 2), ii15-20 (2005).
95. Higgins, D. L. et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127-1134 (2005).
96. Mercier, R. C. & Hrebickova, L. Oritavancin: A new avenue for resistant Gram-positive bacteria. Expert Rev. Anti Infect. Ther. 3, 325-332 (2005).
97. Barrett, M. S., Wenzel, R. P. & Jones, R. N. In vitro activity of mersacidin (M87-1551), an investigational peptide antibiotic tested against gram-positive bloodstream isolates. Diagn. Microbiol. Infect. Dis. 15, 641-644 (1992).
98. Petersen, P. J., Wang, T. Z., Dushin, R. G. & Bradford, P. A. Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against Gram-positive clinical isolates. Antimicrob. Agents Chemother. 48, 739-746 (2004).